Results 91 to 100 of about 1,233,301 (210)

Neuropsychiatric Outcomes Associated With GLP‐1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptors are expressed in brain regions governing mood, reward and stress, yet the neuropsychiatric effects of GLP‐1 receptor agonist (GLP‐1 RA) therapy remain poorly characterized. We estimated associations between GLP‐1 RA use and neuropsychiatric disorders and variation by obesity status and treatment ...
Seo Hyon Baik   +4 more
wiley   +1 more source

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

open access: yesInternal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos   +5 more
wiley   +1 more source

The pathogenetic bases of cardiorenal syndrome

open access: yesТерапевтический архив, 2012
The term "cardiorenal syndrome" has been introduced to denote the mutual influences of the cardiovascular system and kidneys. According to the definition, the cardiorenal syndrome is a pathophysiological condition of the heart and kidney, in which acute ...
I P Beloglazova   +2 more
doaj  

GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications

open access: yesJournal of Internal Medicine, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists provide benefits in weight reduction, glycaemic control in Type 2 diabetes, and cardiovascular and renal outcomes. Their widespread use has given rise to concerns regarding rare but potentially serious adverse events.
Peter Ueda
wiley   +1 more source

Treatment of cardiorenal syndrome

open access: yes, 2017
The thesis describes the treatment methods of cardiorenal syndrome.
Sied Farah, Dollal
core  

Preeclampsia: a gestational cardiorenal syndrome [PDF]

open access: yes, 2019
It is generally accepted today that there are two different types of preeclampsia: an early-onset or placental type and a late-onset or maternal type. In the latent phase, the first one presents with a low output/high resistance circulation eventually ...
Thilaganathan, Basky   +5 more
core   +1 more source

Type 4 cardiorenal syndrome

open access: yesRevista Portuguesa de Cardiologia, 2016
The Acute Dialysis Quality Initiative consensus conference proposed a classification of cardiorenal syndrome (CRS), aiming for a better delineation of each subtype.
Ana Luísa Pinheiro da Silva   +1 more
doaj   +1 more source

Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome

open access: yesExperimental Physiology, EarlyView.
Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis ...
Chunxiang Xu   +5 more
wiley   +1 more source

Dietary interventions in acute kidney injury: From molecular mechanism to clinical trials

open access: yesExperimental Physiology, EarlyView.
Abstract Ageing impairs renal resilience with an elevated risk of frequent and harmful acute kidney injury (AKI) that causes substantial morbidity and mortality among hospitalized patients. Since different damaging stimuli at the molecular, cellular and functional level contribute to this loss in kidney function, AKI's pathophysiology is heterogeneous ...
Felix C. Koehler   +2 more
wiley   +1 more source

Gene‐Guided Therapy in Type 2 Diabetes Mellitus: An Integrative Review of the Pharmacogenetics of Metformin and Sodium‐Glucose Cotransporter‐2 Inhibitors

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 6, November 2026.
Genetic variation influences the pharmacological response to metformin and SGLT2 inhibitors in patients with type 2 diabetes mellitus. Pharmacogenetic biomarkers affecting drug transport, metabolism and target activity contribute to inter‐individual differences in treatment efficacy and adverse effects, supporting the implementation of personalized ...
Imran Hossain   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy